Trexquant Investment LP Raises Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE)

Trexquant Investment LP boosted its stake in Fate Therapeutics, Inc. (NASDAQ:FATE – Get Rating) by 621.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 62,888 shares of the biopharmaceutical company’s stock after purchasing an additional 54,168 shares during the period. Trexquant Investment LP owned approximately 0.06% of Fate Therapeutics worth $1,409,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in FATE. State Street Corp increased its holdings in Fate Therapeutics by 51.8% in the 2nd quarter. State Street Corp now owns 5,270,135 shares of the biopharmaceutical company’s stock valued at $130,594,000 after purchasing an additional 1,797,703 shares in the last quarter. Capital World Investors increased its holdings in Fate Therapeutics by 39.9% in the 1st quarter. Capital World Investors now owns 4,559,673 shares of the biopharmaceutical company’s stock valued at $176,779,000 after purchasing an additional 1,300,640 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in Fate Therapeutics by 378.9% in the 2nd quarter. Goldman Sachs Group Inc. now owns 1,084,670 shares of the biopharmaceutical company’s stock valued at $26,879,000 after purchasing an additional 858,193 shares in the last quarter. Pictet Asset Management SA increased its holdings in Fate Therapeutics by 54.7% in the 2nd quarter. Pictet Asset Management SA now owns 2,102,161 shares of the biopharmaceutical company’s stock valued at $52,092,000 after purchasing an additional 743,525 shares in the last quarter. Finally, Artal Group S.A. increased its holdings in Fate Therapeutics by 30.0% in the 2nd quarter. Artal Group S.A. now owns 2,600,000 shares of the biopharmaceutical company’s stock valued at $64,428,000 after purchasing an additional 600,000 shares in the last quarter.

Insider Activity

In other Fate Therapeutics news, Director John Mendlein purchased 88,048 shares of the business’s stock in a transaction dated Wednesday, January 11th. The shares were bought at an average price of $5.67 per share, with a total value of $499,232.16. Following the completion of the acquisition, the director now owns 246,139 shares in the company, valued at approximately $1,395,608.13. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, CEO J Scott Wolchko sold 45,907 shares of Fate Therapeutics stock in a transaction that occurred on Tuesday, January 10th. The stock was sold at an average price of $5.24, for a total transaction of $240,552.68. Following the sale, the chief executive officer now owns 385,639 shares of the company’s stock, valued at $2,020,748.36. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director John Mendlein purchased 88,048 shares of the business’s stock in a transaction dated Wednesday, January 11th. The shares were acquired at an average cost of $5.67 per share, for a total transaction of $499,232.16. Following the acquisition, the director now owns 246,139 shares of the company’s stock, valued at approximately $1,395,608.13. The disclosure for this purchase can be found here. Over the last 90 days, insiders have sold 75,708 shares of company stock valued at $396,710. Insiders own 17.34% of the company’s stock.

Fate Therapeutics Price Performance

Shares of NASDAQ FATE opened at $4.88 on Monday. The firm’s 50-day moving average price is $6.29 and its two-hundred day moving average price is $15.71. Fate Therapeutics, Inc. has a 52-week low of $4.02 and a 52-week high of $43.12.

Fate Therapeutics (NASDAQ:FATE – Get Rating) last issued its earnings results on Tuesday, February 28th. The biopharmaceutical company reported ($0.58) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.86) by $0.28. Fate Therapeutics had a negative net margin of 292.55% and a negative return on equity of 50.86%. The firm had revenue of $44.36 million for the quarter, compared to analysts’ expectations of $18.41 million. During the same quarter last year, the company posted ($0.72) earnings per share. Fate Therapeutics’s revenue was up 159.9% on a year-over-year basis. On average, analysts predict that Fate Therapeutics, Inc. will post -2.14 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on FATE. StockNews.com downgraded Fate Therapeutics from a “hold” rating to a “sell” rating in a report on Friday. SVB Leerink lowered their target price on Fate Therapeutics from $62.00 to $10.00 and set an “outperform” rating for the company in a research note on Friday, January 6th. HC Wainwright downgraded Fate Therapeutics from a “buy” rating to a “neutral” rating and lowered their target price for the company from $115.00 to $7.00 in a research note on Tuesday, January 24th. Bank of America downgraded Fate Therapeutics from a “buy” rating to an “underperform” rating in a research note on Friday, January 6th. Finally, Oppenheimer downgraded Fate Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Thursday, December 22nd. Three investment analysts have rated the stock with a sell rating, fourteen have given a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, Fate Therapeutics has an average rating of “Hold” and an average target price of $24.69.

Fate Therapeutics Company Profile

(Get Rating)

Fate Therapeutics, Inc engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D.